Stefan D. Anker has been Professor of (Tissue) Homeostasis in Cardiology & Metabolism at Charité Berlin, Germany, since June 2017. He studied medicine at Charité Berlin and completed his clinical training in Germany and the UK. He obtained his MD from Charité Medical School, Berlin (1993) and his PhD (1998) at the National Heart & Lung Institute of Imperial College London, UK. He was Professor of Cardiology & Cachexia Research at Charité from 2002 to 2014, and Professor of Innovative Clinical Trials in Göttingen, Germany, from 2014 to 2017.

Prof. Anker has authored more than 900 original papers, reviews, and editorials that are well cited (total citations: >80,000, h-index: 124, source: Scopus, February 2020). For his work, Prof. Anker has won several prizes and obtained a number of fellowships and grants.

Prof. Anker was Vice President of the European Society of Cardiology (ESC, 2016-18), serving on the ESC board from 2012 to 2018. He has been serving on the board of the Heart Failure Association (HFA) of the ESC since 2006 and was HFA President from 2012 to 2014). He currently chairs the HFA committee on regulatory affairs. He is founding Editor-in-Chief of the first open-access heart failure journal, ESC Heart Failure. Prof. Anker has served on several ESC Guideline task forces.

Prof. Anker is the founding president of the International Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD) and founding Editor-in-Chief of the Journal of Cachexia, Sarcopenia and Muscle. He was and is a member of more than 30 international clinical trial steering committees, chairing or co-chairing several currently (FAIR-HF2, EMPEROR-HFpEF, RESHAPE-HF2, RELIEVE-HF & DIAMOND) as well as in the past (including FAIR-HF, TIM-HF, AUGMENT-HF & BACH). He has also served on a number of data monitoring committees (chairing four) and end-point committees (chairing four).